Overview

A Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GNS-3545 in Healthy Participants

Status:
RECRUITING
Trial end date:
2026-10-31
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled Phase 1 study of SAD (Part 1) and MAD (Part 2) of orally administered GNS-3545 in healthy adult subjects. The food effect will be assessed in one cohort in Part 1.
Phase:
PHASE1
Details
Lead Sponsor:
Genosco Inc.